标题
IgA nephropathy: an overview of drug treatments in clinical trials
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 31, Issue 12, Pages 1321-1338
出版商
Informa UK Limited
发表日期
2023-01-02
DOI
10.1080/13543784.2022.2160315
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Galactose-Deficient IgA1 B cells in the Circulation of IgA Nephropathy Patients Carry Preferentially Lambda Light Chains and Mucosal Homing Receptors
- (2022) Katerina Zachova et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- POS-546 EFFICACY AND SAFETY OF IPTACOPAN IN IgA NEPHROPATHY: RESULTS OF A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 STUDY AT 6 MONTHS
- (2022) J. Barratt et al. Kidney International Reports
- An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
- (2022) Teresa Salvatore et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy
- (2022) Jicheng Lv et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- FC052: Atrasentan for the Treatment of IGA Nephropathy: Interim Results from the Affinity Study
- (2022) Sung-Gyun Kim et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
- (2022) et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Real-World Effectiveness of Belimumab in Systemic Lupus Erythematosus: A Systematic Literature Review
- (2022) Shirley P. Huang et al. Rheumatology and Therapy
- Immunologic Responses After COVID-19 Vaccination in Patients With Membranous Nephropathy Receiving Anti–CD38 Felzartamab Therapy: Results From the Phase 1b/2a M-PLACE Study
- (2022) Brad H. Rovin et al. Kidney International Reports
- Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial
- (2022) Andrew S. Bomback et al. Kidney International Reports
- Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
- (2022) Colin Baigent et al. LANCET
- CD38 and Regulation of the Immune Response Cells in Cancer
- (2021) Sanyog Dwivedi et al. Journal of Oncology
- SGLT-2 inhibition in IgA nephropathy: the new standard of care?
- (2021) Jonathan Barratt et al. KIDNEY INTERNATIONAL
- A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
- (2021) David C. Wheeler et al. KIDNEY INTERNATIONAL
- Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial
- (2021) Antonio M Risitano et al. Lancet Haematology
- Rifaximin as a Potential Treatment for IgA Nephropathy in a Humanized Mice Model
- (2021) Vincenzo Di Leo et al. Journal of Personalized Medicine
- POS-830 NEFECON FOR THE TREATMENT OF IgA NEPHROPATHY IN PATIENTS AT RISK OF PROGRESSING TO END-STAGE RENAL DISEASE: THE NEFIGARD PHASE 3 TRIAL RESULTS
- (2021) J. BARRATT et al. Kidney International Reports
- Telitacicept: First Approval
- (2021) Sohita Dhillon DRUGS
- Pegcetacoplan: First Approval
- (2021) Sheridan M. Hoy DRUGS
- Co-occurrence of IgA nephropathy and IgG4-Tubulointersitial nephritis effectively treated with tacrolimus: a case report
- (2021) Mi Tian et al. BMC Nephrology
- After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy.
- (2020) Thomas Rauen et al. KIDNEY INTERNATIONAL
- Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders
- (2020) Celine Kaegi et al. Frontiers in Immunology
- MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial
- (2020) Marc S Raab et al. Lancet Haematology
- P0344NEFECON® (BUDESONIDE) SELECTIVELY REDUCES CIRCULATING LEVELS OF BAFF (BLYS) AND SOLUBLE BCMA AND TACI IN IGA NEPHROPATHY
- (2020) Karen Molyneux et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy
- (2020) Richard Lafayette et al. Kidney International Reports
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
- (2020) Richard Furie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Monitoring Immune Responses in IgA Nephropathy: Biomarkers to Guide Management
- (2020) Haresh Selvaskandan et al. Frontiers in Immunology
- High levels of gut-homing immunoglobulin A–positive+B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients
- (2020) Fabio Sallustio et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy
- (2019) Aliza Thompson et al. Clinical Journal of the American Society of Nephrology
- A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy
- (2019) James R. Myette et al. KIDNEY INTERNATIONAL
- New strategies and perspectives on managing IgA nephropathy
- (2019) Haresh Selvaskandan et al. Clinical and Experimental Nephrology
- Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
- (2019) Hiddo J L Heerspink et al. LANCET
- GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials
- (2019) Lesley A. Inker et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational Data
- (2019) Morgan E. Grams et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy
- (2019) Christine Barrett et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy
- (2019) Fernando C. Fervenza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Multiple Dosages of Fostamatinib in Adult Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
- (2019) Yaqi Kang et al. Frontiers in Pharmacology
- The role of complement in IgA nephropathy
- (2019) Agustin Tortajada et al. MOLECULAR IMMUNOLOGY
- Predictive value of mesangial C3 and C4d deposition in IgA nephropathy
- (2019) Ki Heon Nam et al. CLINICAL IMMUNOLOGY
- GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics
- (2018) Aaron D. Springer et al. Nucleic Acid Therapeutics
- Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus
- (2018) Joan T. Merrill et al. Arthritis & Rheumatology
- Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial
- (2018) Joan T Merrill et al. ANNALS OF THE RHEUMATIC DISEASES
- OUP accepted manuscript
- (2018) NEPHROLOGY DIALYSIS TRANSPLANTATION
- The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies
- (2018) Maja M. Janas et al. TOXICOLOGIC PATHOLOGY
- Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study
- (2018) Austin G. Kulasekararaj et al. BLOOD
- DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS
- (2018) Howard Trachtman et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Protein PEGylation for cancer therapy: bench to bedside
- (2018) Vijayalaxmi Gupta et al. Journal of Cell Communication and Signaling
- Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy
- (2017) Jicheng Lv et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis
- (2017) David R.W. Jayne et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group
- (2017) Hernán Trimarchi et al. KIDNEY INTERNATIONAL
- Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial
- (2017) Bengt C Fellström et al. LANCET
- TO012C5A RECEPTOR INHIBITOR AVACOPAN IN IGA NEPHROPATHY STUDY
- (2017) Annette Bruchfeld et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Mycophenolate mofetil therapy in immunoglobulin A nephropathy: histological changes after treatment
- (2017) Hannah Beckwith et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date
- (2017) Aleksander Lenert et al. Drug Design Development and Therapy
- Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis
- (2016) Lesley A. Inker et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLyS/APRIL fusion protein, in patients with rheumatoid arthritis
- (2016) Xia Chen et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy
- (2016) Martina Ahlmann et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction
- (2016) Richard A. Lafayette et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- A Multicenter Study of the Predictive Value of Crescents in IgA Nephropathy
- (2016) Mark Haas et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Increased APRIL Expression Induces IgA1 Aberrant Glycosylation in IgA Nephropathy
- (2016) Ya-Ling Zhai et al. MEDICINE
- Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials
- (2016) Sumit Kunwar et al. RHEUMATOLOGY INTERNATIONAL
- Randomized Controlled Trial of Mycophenolate Mofetil in Children, Adolescents, and Adults With IgA Nephropathy
- (2015) Ronald J. Hogg et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Role of IgA receptors in the pathogenesis of IgA nephropathy
- (2015) Sebastian M. Lechner et al. JOURNAL OF NEPHROLOGY
- Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation
- (2015) Xia-Hong Shen et al. JOURNAL OF NEPHROLOGY
- Correlation of disease activity in proliferative glomerulonephritis with glomerular spleen tyrosine kinase expression
- (2015) Stephen P. McAdoo et al. KIDNEY INTERNATIONAL
- Intensive Supportive Care plus Immunosuppression in IgA Nephropathy
- (2015) Thomas Rauen et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study
- (2014) R A Furie et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)
- (2014) David Isenberg et al. ANNALS OF THE RHEUMATIC DISEASES
- Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy
- (2014) Yusuke Suzuki et al. Clinical and Experimental Nephrology
- Association of C4d Deposition with Clinical Outcomes in IgA Nephropathy
- (2014) M. Espinosa et al. Clinical Journal of the American Society of Nephrology
- Specific calcineurin targeting in macrophages confers resistance to inflammation via MKP-1 and p38
- (2014) A. Escolano et al. EMBO JOURNAL
- Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments
- (2014) Rosanna Coppo et al. KIDNEY INTERNATIONAL
- Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens
- (2014) Krzysztof Kiryluk et al. NATURE GENETICS
- Pathology of IgA nephropathy
- (2014) Ian S. D. Roberts Nature Reviews Nephrology
- Eculizumab treatment for rescue of renal function in IgA nephropathy
- (2014) Therese Rosenblad et al. PEDIATRIC NEPHROLOGY
- Microbiota and Metabolome Associated with Immunoglobulin A Nephropathy (IgAN)
- (2014) Maria De Angelis et al. PLoS One
- C3a, C5a Renal Expression and Their Receptors are Correlated to Severity of IgA Nephropathy
- (2013) Lu Liu et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features
- (2013) Gang Xin et al. JOURNAL OF NEPHROLOGY
- IgA Nephropathy
- (2013) Robert J. Wyatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tacrolimus Decreases Albuminuria in Patients with IgA Nephropathy and Normal Blood Pressure: A Double-Blind Randomized Controlled Trial of Efficacy of Tacrolimus on IgA Nephropathy
- (2013) Yong-Chul Kim et al. PLoS One
- Functional Implications of Regulatory B Cells in Human IgA Nephropathy
- (2013) Y.-Y. Wang et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study
- (2012) Brad H. Rovin et al. ARTHRITIS AND RHEUMATISM
- Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies
- (2012) Muhammad Baluom et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Spleen Tyrosine Kinase Is Important in the Production of Proinflammatory Cytokines and Cell Proliferation in Human Mesangial Cells following Stimulation with IgA1 Isolated from IgA Nephropathy Patients
- (2012) M. J. Kim et al. JOURNAL OF IMMUNOLOGY
- Autoantibodies Targeting Galactose-Deficient IgA1 Associate with Progression of IgA Nephropathy
- (2012) F. Berthoux et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression
- (2012) Na Zhao et al. KIDNEY INTERNATIONAL
- Pathogenesis of IgA nephropathy
- (2012) Kar Neng Lai Nature Reviews Nephrology
- Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial
- (2012) Ellen M Ginzler et al. ARTHRITIS RESEARCH & THERAPY
- Chapter 10: Immunoglobulin A nephropathy
- (2012) Kidney International Supplements
- Mice overexpressing BAFF develop a commensal flora–dependent, IgA-associated nephropathy
- (2011) Douglas D. McCarthy et al. JOURNAL OF CLINICAL INVESTIGATION
- New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria
- (2011) H. K. Smerud et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Enhancement of Polymeric Immunoglobulin Receptor Transcytosis by Biparatopic VHH
- (2011) Chris D. Emmerson et al. PLoS One
- Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab
- (2010) H. E. Mei et al. BLOOD
- Glucocorticoids protect renal mesangial cells from apoptosis by increasing cellular sphingosine-1-phosphate
- (2010) Ankathrin Förster et al. KIDNEY INTERNATIONAL
- Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
- (2010) John H. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Eculizumab
- (2009) Eline A. Dubois et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help
- (2009) S. Heidt et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Avosentan Reduces Albumin Excretion in Diabetics with Macroalbuminuria
- (2009) R. R. Wenzel et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification
- (2009) Daniel C. Cattran et al. KIDNEY INTERNATIONAL
- Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy
- (2009) C. Manno et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Levels of Urinary Complement Factor H in Patients with IgA Nephropathy are Closely Associated with Disease Activity
- (2009) J.-J. Zhang et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Concordant Regulation of Translation and mRNA Abundance for Hundreds of Targets of a Human microRNA
- (2009) David G. Hendrickson et al. PLOS BIOLOGY
- Combination Therapy of Prednisone and ACE Inhibitor Versus ACE-Inhibitor Therapy Alone in Patients With IgA Nephropathy: A Randomized Controlled Trial
- (2008) Jicheng Lv et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Mechanism and Regulation of Class Switch Recombination
- (2008) Janet Stavnezer et al. Annual Review of Immunology
- Serum under-galactosylated IgA1 is increased in Japanese patients with IgA nephropathy
- (2008) S. Shimozato et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- IgA Glycosylation and IgA Immune Complexes in the Pathogenesis of IgA Nephropathy
- (2008) Jan Novak et al. SEMINARS IN NEPHROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More